Klaria´s CEO Scott Boyer interviewed in Upsala Nya Tidning about the new pain project
Read about the new pain project: http://unt.se/nyheter/uppsala/cannabinoider-i-nytt-lakemedel-4988412.aspx
About Klaria Pharma Holding AB (publ.)
Klarias business concept is based on developing innovative products with clear competitive advantages in the therapy areas of migraine and breakthrough cancer pain. Klaria’s products are based on a patented drug delivery film which is combined with clinically-tested and established active drugs substances. Klaria is listed on Nasdaq First North under the name KLAR. FNCA Sweden is the Certified Advisor for Klaria Pharma Holding AB. The complete company description can be downloaded from klaria.com. For more information, please visit www.klaria.com.